Patents by Inventor Matthias Austen

Matthias Austen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL NEURTURIN CONJUGATES FOR PHARMACEUTICAL USE
    Publication number: 20160060317
    Abstract: The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability.
    Type: Application
    Filed: April 8, 2015
    Publication date: March 3, 2016
    Inventors: Matthias Austen, Marcus Geese, Rainer Mussmann, Friedrich Harder, Thomas Siegmund, Martin Schneider
  • Screening methods for compounds useful for treating pancreatic dysfunction
    Patent number: 9049849
    Abstract: The present invention discloses polynucleotides which identify and encode DP119, DP444, DP810, DP685, WE474, DP160, RA977, or RA770 as well as novel functions for these proteins of the inventions. The invention provides for compositions for disorders associated with the expression of the proteins of the invention, such as for the treatment, alleviation and/or prevention of pancreatic dysfunction (for example diabetes, hyperglycemia, and impaired glucose tolerance), and related disorders, and other disease and disorders.
    Type: Grant
    Filed: February 18, 2011
    Date of Patent: June 9, 2015
    Assignee: EVOTEC INTERNATIONAL GMBH
    Inventors: Cord Dohrmann, Matthias Austen
  • Neurturin conjugates for pharmaceutical use
    Patent number: 9029323
    Abstract: The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability.
    Type: Grant
    Filed: May 5, 2010
    Date of Patent: May 12, 2015
    Assignee: Evotec International GmbH
    Inventors: Matthias Austen, Marcus Geese, Rainer Mussmann, Friedrich Harder, Thomas Siegmund, Martin Schneider
  • Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions
    Patent number: 8853193
    Abstract: The present invention relates to novel thienopyrimidine compounds of general formula pharmaceutical compositions comprising these compounds and their therapeutic use for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: October 7, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Armin Heckel, Frank Himmelsbach, Joerg Kley, Thorsten Lehmann-Lintz, Norbert Redemann, Achim Sauer, Leo Thomas, Dieter Wiedenmayer, Phillip Black, Wesley Blackaby, Ian Linney, Matthias Austen, John Danilewicz, Martin Schneider, Kay Schreiter
  • METHOD FOR PREVENTING AND TREATING DIABETES USING NEURTURIN
    Publication number: 20140274897
    Abstract: The present invention relates generally to methods for preventing and/or treating pancreatic disorders, particularly those related to diabetes, by administering a neurturin protein product.
    Type: Application
    Filed: May 27, 2014
    Publication date: September 18, 2014
    Applicant: EVOTEC INTERNATIONAL GMBH
    Inventors: Matthias Austen, Ulrike Burk
  • Method for promoting regeneration of pancreatic beta-cells by administering neurturin
    Patent number: 8772233
    Abstract: The present invention relates generally to methods for preventing and/or treating pancreatic disorders, particularly those related to diabetes, by administering a neurturin protein product.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: July 8, 2014
    Assignee: Evotec International GmbH
    Inventors: Matthias Austen, Ulrike Burk
  • Cycloalkyl containing thienopyrimidines for pharmaceutical compositions
    Patent number: 8754079
    Abstract: The present invention relates to novel thienopyrimidine compounds of general formula pharmaceutical compositions comprising these compounds and their therapeutic use for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: June 17, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thorsten Lehmann-Lintz, Armin Heckel, Joerg Kley, Elke Langkopf, Norbert Redemann, Achim Sauer, Leo Thomas, Dieter Wiedenmayer, Matthias Austen, John Danilewicz, Martin Schneider, Kay Schreiter, Phillip Black, Wesley Blackaby, Ian Linney
  • FORMULATION FOR INCREASING BIOAVAILABILITY OF NEURTURIN
    Publication number: 20140162948
    Abstract: The present invention relates to formulations with protein growth factors, particularly neurturin as active ingredients and low molecular weight polyanionic excipients having increased bioavailability.
    Type: Application
    Filed: September 26, 2013
    Publication date: June 12, 2014
    Applicant: EVOTEC INTERNATIONAL GMBH
    Inventors: Friedrich Harder, Matthias Austen
  • Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions
    Patent number: 8648068
    Abstract: The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: February 11, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thorsten Lehmann-Lintz, Joerg Kley, Norbert Redemann, Achim Sauer, Leo Thomas, Dieter Wiedenmayer, Matthias Austen, John Danilewicz, Martin Schneider, Kay Schreiter, Phillip Black, Wesley Blackaby, Ian Linney
  • NOVEL NEURTURIN CONJUGATES FOR PHARMACEUTICAL USE
    Publication number: 20130231283
    Abstract: The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability.
    Type: Application
    Filed: February 1, 2013
    Publication date: September 5, 2013
    Applicant: DeveloGen Aktiengesellschaft
    Inventors: Matthias Austen, Marcus Geese, Rainer Mussmann, Friedrich Harder, Thomas Siegmund, Martin Schneider
  • Thienopyrimidines for pharmaceutical compositions
    Patent number: 8486953
    Abstract: The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
    Type: Grant
    Filed: August 24, 2009
    Date of Patent: July 16, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Austen, Phillip Black, Wesley Blackaby, John Danilewicz, Ian Linney, Kay Schreiter, Martin Schneider
  • Method for treating diabetes using neurturin
    Patent number: 8399408
    Abstract: The present invention relates generally to methods for preventing and/or treating pancreatic disorders, particularly those related to diabetes, by administering a neurturin protein product.
    Type: Grant
    Filed: February 15, 2011
    Date of Patent: March 19, 2013
    Assignee: DeveloGen Aktiengesellschaft
    Inventors: Matthias Austen, Ulrike Burk
  • HALOGEN OR CYANO SUBSTITUTED THIENO [2,3-D]PYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS
    Publication number: 20130065914
    Abstract: The present invention relates to novel thienopyhmidine compounds of general formula (I), pharmaceutical compositions comprising these compounds and their therapeutic use for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
    Type: Application
    Filed: February 25, 2011
    Publication date: March 14, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Armin Heckel, Frank Himmelsbach, Thorsten Lehmann-Lintz, Norbert Redemann, Achim Sauer, Leo Thomas, Phillip Black, Wesley Blackaby, John Danilewicz, Ian Linney, Matthias Austen, Martin Schneider, Kay Schreiter
  • NEW FORMULATION FOR INCREASING BIOAVAILABILITY OF NEURTURIN
    Publication number: 20130053313
    Abstract: The present invention relates to formulations with protein growth factors, particularly neurturin as active ingredients and low molecular weight polyanionic excipients having increased bioavailability.
    Type: Application
    Filed: August 27, 2012
    Publication date: February 28, 2013
    Applicant: DeveloGen Aktiengesellschaft
    Inventors: Friedrich Harder, Matthias Austen
  • THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS
    Publication number: 20120128686
    Abstract: The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
    Type: Application
    Filed: August 24, 2009
    Publication date: May 24, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Matthias Austen, Phillip Black, Wesley Blackaby, John Danilewicz, Ian Linney, Kay Schreiter, Martin Schneider
  • METHODS FOR INCREASING BETA CELL MASS COMPRISING ADMINISTERING A RA770 POLYPEPTIDE
    Publication number: 20110277045
    Abstract: The present invention discloses polynucleotides which identify and encode DP119, DP444, DP810, DP685, WE474, DP160, RA977, or RA770 as well as novel functions for these proteins of the inventions. The invention provides for compositions for disorders associated with the expression of the proteins of the invention, such as for the treatment, alleviation and/or prevention of pancreatic dysfunction (for example diabetes, hyperglycemia, and impaired glucose tolerance), and related disorders, and other disease and disorders.
    Type: Application
    Filed: February 18, 2011
    Publication date: November 10, 2011
    Inventors: Cord Dohrmann, Matthias Austen
  • METHOD FOR PREVENTING AND TREATING DIABETES USING NEURTURIN
    Publication number: 20110256113
    Abstract: The present invention relates generally to methods for preventing and/or treating pancreatic disorders, particularly those related to diabetes, by administering a neurturin protein product.
    Type: Application
    Filed: February 15, 2011
    Publication date: October 20, 2011
    Inventors: Matthias Austen, Ulrike Burk
  • CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS
    Publication number: 20110217311
    Abstract: The present invention relates to novel thienopyrimidine compounds of general formula pharmaceutical compositions comprising these compounds and their therapeutic use for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
    Type: Application
    Filed: February 25, 2011
    Publication date: September 8, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Thorsten LEHMANN-LINTZ, Armin HECKEL, Joerg KLEY, Elke LANGKOPF, Nobert REDEMANN, Achim SAUER, Leo THOMAS, Dieter WIEDENMAYER, Matthias AUSTEN, John DANILEWICZ, Martin SCHNEIDER, Kay SCHREITER, Phillip BLACK, Wesley BLACKABY, Ian LINNEY
  • HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS
    Publication number: 20110212102
    Abstract: The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
    Type: Application
    Filed: February 25, 2011
    Publication date: September 1, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Thorsten LEHMANN-LINTZ, Joerg KLEY, Norbert REDEMANN, Achim SAUER, Leo THOMAS, Dieter WIEDENMAYER, Matthias AUSTEN, John DANILEWICZ, Martin SCHNEIDER, Kay SCHREITER, Phillip BLACK, Wesley BLACKABY, Ian LINNEY
  • THIENOPYRIMIDINES CONTAINING A SUBSTITUTED ALKYL GROUP FOR PHARMACEUTICAL COMPOSITIONS
    Publication number: 20110212103
    Abstract: The present invention relates to novel thienopyrimidine compounds of general formula pharmaceutical compositions comprising these compounds and their therapeutic use for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
    Type: Application
    Filed: February 25, 2011
    Publication date: September 1, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Armin HECKEL, Frank HIMMELSBACH, Joerg KLEY, Thorsten LEHMANN-LINTZ, Norbert REDEMANN, Achim SAUER, Leo THOMAS, Dieter WIEDENMAYER, Phillip BLACK, Wesley BLACKABY, Ian LINNEY, Matthias AUSTEN, John DANILEWICZ, Martin SCHNEIDER, Kay SCHREITER